The Hospiten Sleep Unit incorporates daridorexant into its treatments, a new molecule created by biotechnology with the aim of combating chronic insomnia.
The head of the Clinical Neurophysiology Service of Hospiten and expert in sleep disorders, Dr. Txomin Navajas, recalls that chronic insomnia is known as lack of sleep for three or more days a week that lasts for more than three months. This pathology has traditionally been treated with drugs such as benzodiazepines and hypnotics, two treatments that generate habituation and tolerance in addition to pharmacological sleep.
The Clinical Neurophysiology Service of Hospiten recommends the use of this innovative treatment for chronic insomnia, given its successful results to date, since the daridorexant molecule manages to block the hormones that generate stress (orexins), causing the brain to produce physiological sleep.
Dr. Navajas points out that “among the advantages of daridorexant, it is important to highlight that it does not generate dependence or habituation. It is a safe medication that can be stopped without having to do so gradually. In addition, it is recommended for patients who take any other type of medication.”
“This treatment has been designed through biotechnology to, specifically, lower the levels of those hormones that create wakefulness and give rise to physiological sleep. At Grupo Hospiten, we believe that it is a revolutionary procedure that can greatly change the perspective of treatment in patients with chronic insomnia. Since daridorexant, also already approved in Europe, is safe, has few side effects, does not create tolerance or leave drowsiness the next day,” says Dr. Navajas.
Grupo Hospiten, in its eagerness to incorporate the latest medical advances to solve patients' health problems, considers that sleep problems have become a real epidemic that affects society and that leads to additional problems of depression, the immune system or susceptibility to being overweight. In this sense, insomnia should be treated as a public health problem.
About Grupo Hospiten
Grupo Hospiten is an international healthcare network committed to providing a service of the highest quality, with more than 50 years of experience, which has 20 private medical-hospital centers in Spain, the Dominican Republic, Mexico, Jamaica and Panama, and more than 100 outpatient medical centers, under the Clinic Assist brand. Founded by Dr. Pedro Luis Cobiella, it serves more than two million patients from all over the world annually, and has a staff of more than 5,000 people.
